Free Trial

Altimmune (ALT) Competitors

Altimmune logo
$5.77 +0.18 (+3.22%)
Closing price 05/22/2025 04:00 PM Eastern
Extended Trading
$5.80 +0.03 (+0.43%)
As of 05/22/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ALT vs. BEAM, APGE, SDGR, CNTA, BHC, ARQT, AGIO, GLPG, IRON, and IDYA

Should you be buying Altimmune stock or one of its competitors? The main competitors of Altimmune include Beam Therapeutics (BEAM), Apogee Therapeutics (APGE), Schrödinger (SDGR), Centessa Pharmaceuticals (CNTA), Bausch Health Companies (BHC), Arcutis Biotherapeutics (ARQT), Agios Pharmaceuticals (AGIO), Galapagos (GLPG), Disc Medicine (IRON), and IDEAYA Biosciences (IDYA). These companies are all part of the "pharmaceutical products" industry.

Altimmune vs.

Altimmune (NASDAQ:ALT) and Beam Therapeutics (NASDAQ:BEAM) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, community ranking, earnings, valuation, profitability, dividends, media sentiment and institutional ownership.

Beam Therapeutics has a net margin of -41.07% compared to Altimmune's net margin of -199,076.92%. Beam Therapeutics' return on equity of -16.22% beat Altimmune's return on equity.

Company Net Margins Return on Equity Return on Assets
Altimmune-199,076.92% -55.81% -50.60%
Beam Therapeutics -41.07%-16.22%-10.94%

In the previous week, Altimmune had 13 more articles in the media than Beam Therapeutics. MarketBeat recorded 20 mentions for Altimmune and 7 mentions for Beam Therapeutics. Beam Therapeutics' average media sentiment score of 1.74 beat Altimmune's score of 0.94 indicating that Beam Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Altimmune
7 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Beam Therapeutics
7 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

Beam Therapeutics received 6 more outperform votes than Altimmune when rated by MarketBeat users. However, 72.09% of users gave Altimmune an outperform vote while only 59.13% of users gave Beam Therapeutics an outperform vote.

CompanyUnderperformOutperform
AltimmuneOutperform Votes
62
72.09%
Underperform Votes
24
27.91%
Beam TherapeuticsOutperform Votes
68
59.13%
Underperform Votes
47
40.87%

78.1% of Altimmune shares are owned by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are owned by institutional investors. 4.1% of Altimmune shares are owned by insiders. Comparatively, 4.2% of Beam Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Altimmune has a beta of 1.13, suggesting that its stock price is 13% more volatile than the S&P 500. Comparatively, Beam Therapeutics has a beta of 2.35, suggesting that its stock price is 135% more volatile than the S&P 500.

Altimmune presently has a consensus price target of $20.20, indicating a potential upside of 250.09%. Beam Therapeutics has a consensus price target of $48.75, indicating a potential upside of 182.77%. Given Altimmune's higher possible upside, equities research analysts plainly believe Altimmune is more favorable than Beam Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Altimmune
0 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
3.00
Beam Therapeutics
0 Sell rating(s)
2 Hold rating(s)
11 Buy rating(s)
2 Strong Buy rating(s)
3.00

Altimmune has higher earnings, but lower revenue than Beam Therapeutics. Altimmune is trading at a lower price-to-earnings ratio than Beam Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Altimmune$20K23,399.37-$88.45M-$1.26-4.58
Beam Therapeutics$63.58M27.27-$132.53M-$4.61-3.74

Summary

Beam Therapeutics beats Altimmune on 11 of the 18 factors compared between the two stocks.

Get Altimmune News Delivered to You Automatically

Sign up to receive the latest news and ratings for ALT and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ALT vs. The Competition

MetricAltimmunePharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$467.99M$6.48B$5.33B$8.39B
Dividend YieldN/A2.64%5.21%4.11%
P/E Ratio-3.729.0626.7119.71
Price / Sales23,399.37251.50386.13120.55
Price / CashN/A65.8538.2534.62
Price / Book2.106.456.774.50
Net Income-$88.45M$143.98M$3.23B$248.22M
7 Day Performance-0.17%2.41%1.80%0.56%
1 Month Performance18.97%4.56%11.10%13.17%
1 Year Performance-26.87%-2.67%17.11%7.30%

Altimmune Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ALT
Altimmune
2.6245 of 5 stars
$5.77
+3.2%
$20.20
+250.1%
-26.9%$467.99M$20,000.00-3.7250News Coverage
Analyst Upgrade
Analyst Revision
Gap Up
BEAM
Beam Therapeutics
3.1638 of 5 stars
$18.24
+4.8%
$48.75
+167.3%
-30.7%$1.83B$63.58M-10.36510Positive News
APGE
Apogee Therapeutics
2.1488 of 5 stars
$39.58
+6.1%
$94.60
+139.0%
-15.7%$1.78BN/A-16.3691Positive News
SDGR
Schrödinger
2.9324 of 5 stars
$24.17
+1.1%
$32.80
+35.7%
-6.3%$1.77B$207.54M-10.33790News Coverage
CNTA
Centessa Pharmaceuticals
3.5384 of 5 stars
$13.15
+6.9%
$27.00
+105.3%
+44.2%$1.75B$6.85M-8.59200Positive News
Analyst Upgrade
Insider Trade
Analyst Revision
Gap Up
BHC
Bausch Health Companies
4.1617 of 5 stars
$4.79
+4.2%
$7.42
+55.0%
-29.4%$1.73B$9.73B-39.8719,900Gap Up
ARQT
Arcutis Biotherapeutics
2.7526 of 5 stars
$14.39
+6.4%
$18.80
+30.6%
+37.7%$1.72B$212.82M-8.04150News Coverage
Insider Trade
AGIO
Agios Pharmaceuticals
3.9759 of 5 stars
$29.14
+6.7%
$56.00
+92.2%
-11.5%$1.69B$37.04M2.57390Positive News
GLPG
Galapagos
0.4827 of 5 stars
$25.07
-1.0%
$25.33
+1.1%
+2.1%$1.65B$288.19M0.001,310Positive News
IRON
Disc Medicine
3.1625 of 5 stars
$46.61
+5.4%
$98.80
+112.0%
+44.8%$1.61BN/A-11.7130Positive News
Insider Trade
IDYA
IDEAYA Biosciences
3.6725 of 5 stars
$18.35
+5.3%
$53.58
+192.0%
-54.9%$1.61B$7M-5.5680Analyst Forecast

Related Companies and Tools


This page (NASDAQ:ALT) was last updated on 5/23/2025 by MarketBeat.com Staff
From Our Partners